Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 11,584 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 1 Interventional

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

NCT01519011
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Nov 7, 2026, 5:42 AM EST
Active, not recruiting Phase 2 Interventional

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

NCT02007044
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Quality-of-Life Assessment, Questionnaire Administration, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

NCT00515164
View directory record Official record
Conditions
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
Interventions
Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Drug
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Iowa City, Iowa • Topeka, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of NMES for Reducing Pain and Improving Functional Outcomes in Knee OA Patients

NCT03980964
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions
Active NMES
Device
Lead sponsor
CyMedica Orthopedics, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional

Kidney Transplant for HIV-Infected Patients in Renal Failure

NCT00009009
View directory record Official record
Conditions
Chronic Kidney Failure, HIV Infection
Interventions
immunosuppressive regimen designed to complement HAART
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional Results available

Treating Civilian Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation (ciTBI-HDtDCS)

NCT05408975
View directory record Official record
Conditions
Traumatic Brain Injury, Word Finding Difficulty, Acquired Brain Injury, Cognitive Change
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Phase 1 Interventional

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

NCT06543381
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Olutasidenib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Terminated Not applicable Interventional Results available

Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas

NCT04376567
View directory record Official record
Conditions
End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
Interventions
One stage approach
Procedure
Lead sponsor
Tze-Woei Tan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 7, 2026, 5:42 AM EST
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

NCT05764642
View directory record Official record
Conditions
Healthy, Chronic Kidney Diseases
Interventions
Definity, Super-resolution ultrasound imaging
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NCT00440869
View directory record Official record
Conditions
End-Stage Renal Disease, Dialysis, Hemodialysis
Interventions
N-acetylcysteine, placebo
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Nov 7, 2026, 5:42 AM EST
Completed Early Phase 1 Interventional Results available

Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent

NCT03681769
View directory record Official record
Conditions
Chronic Pain, Opiate Dependence, Lower Back Pain
Interventions
iTBS to the left dlPFC, Sham iTBS to the left dlPFC, cTBS to the mPFC, Sham cTBS to the mPFC
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01466153
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Rituximab, Bendamustine, MEDI-551
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

NCT01938430
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Nov 7, 2026, 5:42 AM EST
Completed No phase listed Observational

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

NCT03739307
View directory record Official record
Conditions
Traumatic Brain Injury, Pain
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years and older
Enrollment
3,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Englewood, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Not applicable Interventional

VR-PMR for Post-Burn Symptoms

NCT07317271
View directory record Official record
Conditions
Burn, Chronic Pain Following Thermal Burn Injury, Non-Pharmacological Interventions, Virtual Reality, Sleep Disturbance, Anxiety, Depressive Symptoms, Fatigue Symptom, Pruritus, Burn Injury, Progressive Muscle Relaxation
Interventions
Virtual Reality-Enhanced Progressive Muscle Relaxation, Standard Progressive Muscle Relaxation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 1Phase 2 Interventional

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional

Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis

NCT00004495
View directory record Official record
Conditions
End Stage Renal Disease, Hyperhomocysteinemia
Interventions
cyanocobalamin, folic acid, pyridoxine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 89 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 7, 2026, 5:42 AM EST
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 1 Interventional

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

NCT05030675
View directory record Official record
Conditions
Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Fostamatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Nov 7, 2026, 5:42 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Exploring the Biological Basis of Chronic Fatigue Syndrome

NCT04859257
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years to 100 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Nov 7, 2026, 5:42 AM EST